Literature DB >> 2127925

Amyotrophic lateral sclerosis: thyroid and prolactin hormone changes in thyrotropin-releasing hormone therapy.

D Testa1, P G Chiodini, F Girotti, R Attanasio.   

Abstract

13 patients with amyotrophic lateral sclerosis (ALS) were treated with intravenous infusion of thyrotropin-releasing hormone (TRH). In 6 patients 2 mg/day of TRH was i.v. given over 2 hours for 10 days. In 7 others 2 mg/day of TRH was continuously infused by means of a pump. An increase of thyroid hormones related to the duration of the treatment was observed. A surprising finding was the onset of prolactin (PRL) response to growth hormone releasing hormone (GHRH), previously absent.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2127925     DOI： 10.1007/bf02337445

Source DB:  PubMed          Journal:  Ital J Neurol Sci        ISSN： 0392-0461


  9 in total

1.  Sustained rises in serum thyrotropin, thyroxine, and triiodothyronine during long term, continuous thyrotropin-releasing hormone treatment in patients with amyotrophic lateral sclerosis.

Authors:  M M Kaplan; J A Taft; S Reichlin; T L Munsat
Journal:  J Clin Endocrinol Metab       Date:  1986-10       Impact factor: 5.958

2.  [Treatment of amyotrophic lateral sclerosis with thyrotropin releasing hormone].

Authors:  G Serratrice; C Desnuelle; A Crevat; C Guelton; A Meyer-Dutour
Journal:  Rev Neurol (Paris)       Date:  1986       Impact factor: 2.607

3.  Amyotrophic lateral sclerosis: effects of acute intravenous and chronic subcutaneous administration of thyrotropin-releasing hormone in controlled trials.

Authors:  H Mitsumoto; E D Salgado; D Negroski; M R Hanson; V D Salanga; J F Wilber; A J Wilbourn; A C Breuer; J Leatherman
Journal:  Neurology       Date:  1986-02       Impact factor: 9.910

4.  The administration of guanidine in amyotrophic lateral sclerosis.

Authors:  F H Norris; P R Calanchini; R J Fallat; S Panchari; B Jewett
Journal:  Neurology       Date:  1974-08       Impact factor: 9.910

Review 5.  Current status of thyrotropin-releasing hormone therapy in amyotrophic lateral sclerosis. Committee on Health Care Issues, American Neurological Association.

Authors: 
Journal:  Ann Neurol       Date:  1987-10       Impact factor: 10.422

6.  The action of thyrotropin-releasing hormone, substance P and related peptides on frog spinal motoneurons.

Authors:  R A Nicoll
Journal:  J Pharmacol Exp Ther       Date:  1978-12       Impact factor: 4.030

7.  Alterations in receptors for thyrotropin-releasing hormone, serotonin, and acetylcholine in amyotrophic lateral sclerosis.

Authors:  S Manaker; S B Caine; A Winokur
Journal:  Neurology       Date:  1988-09       Impact factor: 9.910

8.  Effect on weakness and spasticity in amyotrophic lateral sclerosis of thyrotropin-releasing hormone.

Authors:  W K Engel; T Siddique; J T Nicoloff
Journal:  Lancet       Date:  1983-07-09       Impact factor: 79.321

9.  Changes in growth hormone (GH) secretion induced by human pancreatic GH releasing hormone-44 in acromegaly: a comparison with thyrotropin-releasing hormone and bromocriptine.

Authors:  P G Chiodini; A Liuzzi; D Dallabonzana; G Oppizzi; G G Verde
Journal:  J Clin Endocrinol Metab       Date:  1985-01       Impact factor: 5.958
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.